The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A ...
The British pharmaceutical group said it would continue to work with U.S. regulators on a review of its breast-cancer ...
The FDA’s Oncologic Drugs Advisory Committee (ODAC) on Thursday voted 6 to 3 that AstraZeneca has not demonstrated its oral ...
The FDA’s real-time clinical trial mechanism allows drug sponsors to transmit data immediately to the regulator through the ...
By Pushkala Aripaka and Maggie Fick April 29 (Reuters) - AstraZeneca beat first-quarter profit expectations and maintained ...
Sir Kier Starmer announces the multi-million-pound investment in the House of Commons.
The FDA is looking at a slew of label expansions this month, including one that could open up home-based treatments for Alzheimer’s disease.
AstraZeneca has paid $25 million to pick up a preclinical EGFR degrader that was at the center of its existing pact with ...
As AstraZeneca braces for the impact of the U.S. “most favored nation” drug pricing policy, CEO Pascal Soriot suggests that a ...
LONDON, April 29 (Reuters) - Prime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results